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Trends in incidence, mortality, and causes
of death associated with systemic sclerosis
in Denmark between 1995 and 2015: a
nationwide cohort study
Sheraz A. Butt1* , Jørgen L. Jeppesen1, Christine Fuchs2, Mette Mogensen2, Merete Engelhart3,
Christian Torp-Pedersen4, Gunnar H. Gislason5, Søren Jacobsen6 and Charlotte Andersson5
Abstract
Background: To investigate the incidence and the mortality-rates of systemic sclerosis (SSc), its primary causes of
death, and the temporal trends in events in Denmark during the last decades.
Methods: Using the Danish National Patient Registry, we identified all persons aged ≥18 years with a first-time
diagnosis of SSc (ICD-10 code M34, excluding M34.2) between 1995 and 2015.
Results: A total of 2778 incident SSc cases were identified. The mean age at time of SSc diagnosis was 56 (standard
deviation 15) years and 76% were women. The overall incidence rate (per 1,000,000 person-years) of diagnosed SSc
was 24.4 (95% confidence interval 23.6–25.4), with a slight increase over the study period, age- and sex-adjusted
incidence rate ratio 1.02 (95% confidence interval 1.01–1.02) per 1-year increase. The 1-year all-cause mortality rate
per 100 person-years decreased from 6.1 (3.1–12.2) in 1995 to 5.3 (2.5–11.1) in 2015, sex- and age-adjusted hazard
ratio 0.96 (95% CI 0.94–0.98) per 1-year increase. Over the period, the average age at SSc diagnosis increased and
the proportion of women decreased, whereas the burden of comorbidities increased. One fifth of all deaths were
attributable to cardiovascular causes, a fourth to pulmonary diseases, and 15% were due to cancer.
Conclusions: Within the last few decades, the incidence of SSc has increased and the 1-year mortality rate has
decreased slightly in Denmark. Almost half of all deaths were attributable to cardiopulmonary causes.
Keywords: Systemic sclerosis, Scleroderma, Incidence, Mortality, Cause of death, Epidemiology
Background
Systemic sclerosis (SSc) is a heterogenic systemic auto-
immune connective tissue disease characterized by
humoral and cellular immune dysregulation resulting in
vasculopathy and progressive fibrosis of the skin and
visceral organs. SSc is also associated with substantially
increased morbidity and mortality compared with the
general population [1, 2].
Epidemiologically, SSc has been difficult to characterize
due to its rarity, heterogeneity, imprecise date of onset
and difficulty in case ascertainment. Consequently, large
variability in estimates of incidence and mortality rates
have been reported in prior studies [3]. Due to its rarity
and imprecise date of onset, large datasets with continu-
ous registration of diagnoses, such as nationwide adminis-
trative data, are needed to get more precise estimates of
the incidence and mortality, and to investigate changes in
these measures over time.
The question about trends over time is particularly in-
teresting in the setting of SSc, as an increasing incidence
of several autoimmune disorders has been noted over the
last few decades [4] and there is some evidence that also
the incidence of SSc may also been increasing [5, 6]. Simi-
lar, the survival over the past decades may have improved,
but sparse data are available, especially on causes of death
[1, 3, 7–9]. The SSc population in Denmark has been
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scarcely depicted [10]. In this study, we therefore aimed to
estimate the incidence and the mortality rates of SSc
in Denmark. We also investigated underlying causes of
deaths and if these measures have changed during
1995 to 2015.
Methods
Data sources
All Danish citizens are given a permanent civil registra-
tion number at the time of birth or immigration. This
number is used in every contact with the hospital system
and at the central population registry, where all births
and deaths (including dates) are registered. For the
present study, we cross-linked the central population
registry with the nationwide Danish National Patient
Register (DNPR), which contains information on all in
and out hospital visits. In brief, the DNPR is held by the
Danish government in order to keep statistics of re-
sources and needs of medical care. All medical care is
tax funded and equally available to Danish citizens. For
each visit to the hospital, patients are assigned one main
diagnosis and any secondary diagnoses of relevance to
the current hospital contact upon discharge. Financial re-
imbursement to the hospital departments is pending on the
diagnostic codes, which makes a great incitement for cor-
rect coding. The diagnostic codes have been based on the
international classification of diseases (ICD) 10th version
system since 1994. Between 1978 (when the hospitalization
registry was established) and 1993 the codes were based on
the ICD 8th version. The ICD-9 coding system was never
implemented in Denmark. The diagnostic codes utilized in
this study are presented in Additional file 1. Causes of death
are available from the National Causes of Death Registry.
All causes of deaths (primary and any contributing causes)
are registered with ICD-10 codes and assessed by the treat-
ing physicians or based on autopsy reports, if available.
Study population
The definition of SSc in this study was based on a
first-time registration of SSc using ICD-10 codes M34
except for M34.2 in the DNPR following outpatient or
inpatient visits between 1995 and 2015. To ensure inclu-
sion of only incident cases, we excluded patients with a
prior diagnosis of SSc, defined as an ICD-10 code in
1994 or an ICD-8 code of 734 anytime between 1978
and 1993.
Validation
In the DNPR, the accuracy and completeness of
discharge data have been shown to be high for most
diagnoses [11]. Prior epidemiological studies have used
the SSc diagnosis from the DNPR under the assumption
that the quality of the hospital registry data is high be-
cause patients with SSc are almost exclusively treated in
specialized departments of rheumatology and dermatol-
ogy [12]. Patients with SSc are usually seen at outpatient
clinics where a diagnosis is typically made and registered
in the DNPR. We further validated the ICD-10 diagnosis
of SSc by reviewing charts at hospitals involved in the
treatment of SSc patients in the Eastern Denmark. Up to
30 consecutive patients were identified in the period
2005–2010 based on DNPR data from each of three
departments (two departments of rheumatology and one
department of dermatology) at three different hospitals.
The chosen departments were chosen to represent one
highly specialized and two ordinary referral centers for
connective tissue diseases reflecting the common referral
process in Denmark. The study sample and period for
validation was chosen based on feasibility and the sam-
ple is therefore not a completely random sample of all
SSc patients in Denmark (as three departments were
chosen). In total, 86 patients (26, 30, and 30 patients
from each department, respectively) had available elec-
tronic charts and hereof 81 patients fulfilled the 2013
ACR/EULAR criteria for SSc, corresponding to a posi-
tive predictive value of 94%.
Statistics
Incidence and mortality rates for SSc (by calendar year)
were calculated using all Danish inhabitants who were
alive per the 1st of January and who turned 18 years of
age during the year. One-year mortality for SSc-cases
was defined with first registration of diagnosis and
censored at death or at 365 days follow-up. For the back-
ground population the 1-year mortality was defined per
calendar year. Age was calculated at the 31st of December
for each year. 95% confidence intervals (CIs) of the esti-
mates were calculated under the assumption of a Poisson
distribution and were used to assess if the annual rates
may be fluctuating randomly. A Poisson regression ana-
lysis was used to calculate age- and sex adjusted incidence
rate ratios per 1-year increase to investigate the trends
over time (between 1995 and 2015). Trends in mortality
rates per 1-year increase in calendar time (between 1995
and 2015) among SSc patients were also estimated using
age- and sex adjusted Cox proportional hazard regression
models. Standardized mortality rates (SMR), used as a
mean to compare rates with the background population
within selected strata, were calculated by dividing the
mortality rate of SSc patients with the mortality rate in a
corresponding age- and sex stratum of the background
population. Test for differences in distribution of patient
characteristics (within calendar bins of 1995–2001, 2002–
2008, 2009–2015) was done by the ANOVA test (for con-
tinuous variables) and by the Cochran-Armitage trend test
(for discrete variables), respectively. Similar, tests for
differences in distributions of 1-year causes of death
between the early (1995–2005) and late (2006–2015)
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study period was done by the Chi-squared test. Two-sided
p-values < 0.05 were considered statistically significant for
all analyses. All analyses were performed in SAS version
9.4 (Cary, NC, USA).
Ethics
The study was approved by the Danish Data Protection
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018). As
a retrospective registry-based study, Danish law does not
require ethical approval. The chart review for the valid-
ation process was approved by the Danish Patient Safety
Authority and the permission was granted based on the
assumption that only physicians at a given department
reviewed its own patients’ charts.
Results
Population characteristics
Between 1995 and 2015 a total of 2778 patients with
a first-time SSc diagnoses were identified. The mean
age at the time of diagnosis was around the middle
of the 5th decade of life, but increased slightly
throughout the study period. The proportion of
women was 76% for the entire study period, but de-
creased slightly throughout the study period, Table 1.
Diagnosed renal disease, diabetes, treated hyperten-
sion, and prior cancer at the time of the SSc diagno-
sis was more common in the late study period vs.
the earlier periods, whereas the proportion of immigrants
or prior cardiovascular diseases did not change signifi-
cantly during the observational period.
Incidence
Incidence rates peaked around age 60–79 years in men
and at age 50–79 years in women, Fig. 1. Between 1995
and 2015, the incidence rates were slightly increasing,
Fig. 2 and Additional file 2. The corresponding age- and
sex-adjusted incidence rate ratio per year increase was
1.02 (95% CI 1.01–1.02). Similar trends were observed in
analyses of men and women separately, Fig. 3.
Mortality
1-year all-cause mortality was 5.8 (95% 5.0–6.8) per 100 per-
sons among SSc patients. Compared with the background
population, the sex and age-adjusted hazard ratio for 1-year
mortality associated with SSc was 5.5 (95% CI 4.7–6.4).
5-year mortality rates were slightly lower than 1-year mor-
tality rates, 3.7 (95% 3.3–4.1) per 100 person-years, but still
substantially higher than the background population,
Table 2. Full details of mortality rates by calendar-year
for the background population and the SSc patients are
available in Table 2. The mortality rates were highest in
the older age-groups for both men and for women.
When compared to the mortality rate of the back-
ground population, the SMR was, however, highest in
the younger age-groups and declined with increasing
age, Table 3.
As illustrated in Fig. 2 (and in Table 2), the all-cause
1-year mortality rate per 100 person-years decreased from
1995 to 2015 with a sex- and age-adjusted annual hazard
ratio of 0.96 (95% CI 0.94–0.98) per 1-year increase within
the SSc population. Similar trends were noted for both
women and men, Fig. 4. Causes of death for all SSc pa-
tients dying at any time during the observational period
Table 1 Demographics of SSc cases stratified by calendar time
1995–2001 2002–2008 2009–2015 p-value
N 830 887 1061
Mean age 53.7 (15.6) 55.0 (15.3) 56.1 (15.5) 0.0008
Women 652 (79%) 687 (77%) 775 (73%) 0.01
Immigrants 56 (7%) 50 (6%) 86 (8%) 0.20
Cancer 48 (6%) 51 (6%) 101 (10%) 0.001
Chronic obstructive pulmonary disease 12 (1%) 21 (2%) 48 (5%) 0.0002
Treated hypertension (defined as at least 2 antihypertensive agents) 132 (16%) 264 (30%) 471 (44%) < 0.0001
Diabetes 25 (3%) 53 (6%) 61 (6%) 0.007
Upper gastrointestinal ulcer 47 (6%) 62 (7%) 83 (8%) 0.18
Renal disease 18 (2%) 18 (2%) 40 (4%) 0.03
Heart failure 24 (3%) 26 (3%) 34 (3%) 0.91
Prior acute myocardial infarction 28 (3%) 28 (3%) 30 (3%) 0.79
Peripheral artery disease 34 (4%) 34 (4%) 53 (5%) 0.42
Ischemic stroke 13 (2%) 23 (3%) 33 (3%) 0.10
Footnote: Continuous and categorical variables are presented as mean (standard deviation) and as frequencies (%), respectively. All diagnoses were based on ICD-
8 and ICD-10 codes, except for the diabetes mellitus (based on ‘Anatomical Therapeutical Chemical’ codes of antidiabetic medication) and the hypertension
diagnosis, which was based on a validated algorithm with use of at least 2 antihypertensive agents [46], Additional file 1
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are given in Table 4. For the 1-year mortality endpoint
specifically, the primary cause of death was in 22% attrib-
uted to cardiovascular disorders, in 17% to pulmonary
causes, in 9% to cancer, and in 22% to musculoskeletal
causes (the majority being SSc itself without further
specification). These distributions did not differ for
the early (1995–2005) and late (2005–2015) period (all
p > 0.25), except for the musculoskeletal causes which
were statistically more common in the early vs. late
period (29% vs. 7%, p = 0.0007).
Discussion
Using administrative registries of the whole population,
we have herein described the incidence and the mortality
of SSc in Denmark over the last couple of decades. In
keeping with former epidemiologic studies [3, 13], we
Fig. 1 Age and sex stratified incidence rates. Incidence rates per million for men (blue) and women (red) with 95% confidence intervals
Fig. 2 Temporal trends in overall incidence and 1-year mortality rates between 1995 and 2015. Incidence rate (black line) and mortality rate (red line)
with 95% confidence intervals of estimate
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found SSc to be more common in women than in men
with an overall woman: men ratio of approximately 4:1.
The mean age of diagnosis was around the middle of the
5th decade of life, but was slightly increasing between
1995 and 2015. Our main observation includes a small,
but steady increase in incidence rates throughout the
study period. Moreover, incidence rates increased grad-
ually with advancing age until the age of 60–79 years for
men and of 50–79 years for women. These observations
are consistent with the literature [5, 14]. Our second
principle finding was that mortality rates decreased
slightly during the study period. Still, SSc patients
remained to have a substantially increased risk of death,
when compared to the general population at the end of
the study period.
Incidence
Our study extends other studies that have shown an in-
crease in the incidence rate of SSc over recent times.
However, large discrepancies have been noted among
regions and methodological concerns have been raised.
Earlier and smaller studies have reported lower inci-
dence rates in the Northern Europe (Finland, Iceland,
Norway, England) [15–18], as compared to the Southern
Europe (Spain, Greece, France, Italy) [5, 19–22]. This
has led to speculations of a north-south European gra-
dient of SSc. A recent study in Sweden [23], however,
has shown substantially higher rates, with annual inci-
dence rate estimates as high as 19 per million inhabi-
tants, which does not support the existence of such a
gradient. Our study revealed higher incidence rates
than other northern European estimates, with an over-
all incidence rate of 24 per million adults. However, our
study represents the only newer nationwide European
study, whilst almost all other studies have been based
on selected cohorts. Studies in certain geographical
clusters in Italy, England and Australia [3, 24] have
pointed towards unexpectedly high cumulated inci-
dence rates albeit the actual number of patients has
been low. When comparing studies from other conti-
nents over time, recent studies have also shown an
increasing trend in incidence and prevalence rates e.g.
in Australia [25] (22.8 incident cases per million) and
the U.S. [14] (19.3 incident cases per million). In
contrast, low rates have been estimated in Taiwan (10.9
incident cases per million) [26].
Fig. 3 Temporal trends in sex-stratified incidence rates between 1995 and 2015. Incidence rate per million (blue and red lines) with 95%
confidence intervals of estimate
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Due to the absence of common diagnostic criteria
until the eighties and only recent inclusion of milder
and possibly earlier variants of disease, prior estimates
of incidence should be interpreted with caution. Some
of the considerable differences across time, space and
ethnic diversity can be speculated to be due to, in
part at least, the methodology applied in the respect-
ive studies. After the introduction of the ACR/EULAR
2013 criteria some reports have cited a 30–40% in-
crease in incidence and prevalence rates [23], while
others have reported an increase of 26% in the num-
ber of patients fulfilling the disease definition in com-
parison with the 1980 ARA criteria [27, 28]. Our
study found a substantially smaller increase over the
time period than those prior estimates albeit an in-
creased incidence proportion in the latter timespan
from 2008 to 2015 compared to the first from 1995
to 2002. The latter could perhaps also be explained
by e.g. increasing use of serological markers or capil-
laroscopy leading to a diagnosis of early and mild
disease. In contrast to what may be expected with
more sensitive diagnostic criteria (where possibly earl-
ier and milder diseases may be included) our mean
age increased throughout the study period. Similarly,
the demographic characteristics yielded a higher diag-
nosed comorbidity burden within recent years. The
etiology behind this may be multifactorial and in part
due to an ageing population, more adverse lifestyle
manifestations, earlier diagnosis, lower threshold for
treatment, better access to screening programs and
specialized care. The increasing comorbidity however
is also an argument against that less sick people are
included with the new diagnostic criteria. This could
suggest that the observed increase in incidence may,
at least in part, represent a true increase rather than
the substantial increases resulting merely from meth-
odological differences. Yet, the varying diagnostic cri-
teria used over time and the rarity of the disease
prohibit any conclusions on this matter (as discussed
in detail below under the limitations section).
Table 2 SSc mortality rates, SMR and hazard ratios
1-year background
mortality rate
(per 100 PY)
1-year SSc mortality
(no cases)
1-year SSc mortality
rate (per 100 PY)
5-year SSc mortality
(no cases)
5-mortality mortality
rate (per 100 PY)
1-year SMR 1-year hazard
ratio compared
to background
population (age
and sex adjusted)
1995 1.23 (1.23–1.23) 8 6.1 (3.1–12.2) 19 3.1 (2.0–4.8) 5.0 5.3 (2.7–10.6)
1996 1.18 (1.17–1.19) ≤3 2.6 (0.8–8.1) 24 4.6 (3.1–6.8) 2.2 2.1 (0.7–6.4)
1997 1.16 (1.15–1.17) 9 8.7 (4.5–16.6) 24 4.9 (3.3–7.4) 7.5 8.3 (4.4–16.0)
1998 1.12 (1.11–1.13) 15 14.5 (8.8–24.1) 20 4.1 (2.6–6.3) 13.0 14.3 (8.6–23.7)
1999 1.13 (1.11–1.14) 8 5.3 (2.6–10.5) 28 4.0 (2.8–5.8) 4.7 5.2 (2.6–10.4)
2000 1.09 (1.08–1.10) 5 4.9 (2.1–11.9) 13 2.7 (1.6–4.7) 4.5 5.3 (2.2–12.6)
2001 1.10 (1.08–1.10) 9 10.5 (5.5–20.2) 23 6.1 (4.0–9.1) 9.6 9.6 (5.0–18.3)
2002 1.10 (1.09–1.10) 10 8.8 (4.8–16.4) 21 4.0 (2.6–6.1) 8.0 7.6 (4.1–14.1)
2003 1.07 (1.06–1.07) 8 6.7 (3.3–13.3) 27 5.0 (3.4–7.2) 6.3 6.5 (3.3–13.0)
2004 1.03 (1.02–1.03) 5 4.9 (2.0–11.8) 12 2.4 (1.4–4.3) 4.8 5.2 (2.2–12.4)
2005 1.00 (0.99–1.01) 7 6.0 (2.9–12.6) 26 4.9 (3.3–7.2) 6 5.6 (2.7–11.8)
2006 1.00 (1.00–1.01) 5 3.7 (1.5–8.9) 16 2.5 (1.5–4.0) 3.7 4.1 (1.7–9.8)
2007 1.00 (0.99–1.00) 7 5.1 (2.5–10.8) 18 2.8 (1.8–4.4) 5.1 6.2 (3.0–13.0)
2008 0.97 (0.96–0.98) 6 4.5 (2.0–10.0) 19 3.0 (1.9–4.7) 4.6 4.7 (2.1–10.4)
2009 0.97 (0.96–0.98) 11 8.1 (4.5–14.6) 23 3.6 (2.4–5.4) 8.4 8.2 (4.5–14.7)
2010 0.95 (0.94–0.96) 4 2.6 (1.0–7.0) 23 3.2 (2.1–4.8) 2.7 2.8 (1.1–7.4)
2011 0.91 (0.91–0.92) 12 7.2 (4.1–12.8) 25 3.2 (2.2–4.7) 7.9 8.9 (5.1–15.8)
2012 0.90 (0.89–0.91) 5 3.6 (1.6–9.5) 22 NA 4.0 4.8 (2.0–11.5)
2013 0.90 (0.89–0.91) 8 5.5 (2.7–11.0) 22 NA 6.1 6.0 (3.0–12.1)
2014 0.88 (0.87–0.89) 4 2.3 (0.9–6.2) 12 NA 2.6 3.0 (1.1–8.0)
2015 0.90 (0.89–9.90) 7 5.3 (2.5–6.2) 10 NA 5.9 5.6 (2.7–11.8)
Overall 1.02 (1.02–1.03) NA 5.8 (5.0–6.8) 427 3.7 (3.3–4.1) 5.7 5.5 (4.7–6.4)
Footnote: SMR denotes standardized mortality rate (i.e., mortality rate in SSc patients divided by mortality rate in background population). Mortality rates and
hazard ratio are presented with 95% CIs
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Mortality
The increased morbidity and mortality observed in SSc
is well-known, and several meta-analyses have reported
a high overall SMR for SSc ≥ 3 [1, 2, 8]. However, there
are several studies from the 1960’s and onwards indicat-
ing higher survival rates in recent cohorts compared
with older ones [14, 29–31]. These findings are some-
what consistent with our study, with falling 1-year mor-
tality rates from 1995 to 2015, although the observed
decline was rather small. The SMR and hazard ratio
were at the higher end of earlier reported figures with an
overall SMR of 5.7, as compared with prior pooled SMR
estimates of 3–4 [1, 2, 10, 32]. Perhaps, this difference
could be explained by our study being a nationwide co-
hort study and thus more inclusive not limited by sam-
ple size or certain age-groups. Comparing age-groups,
we expectedly (and in accordance with prior studies
[33–36] found that older age of diagnosis was linked to
higher mortality rates. SMR, however, peaked in younger
age-groups and was not significantly different in males
and females. Such findings were also noted in a prior
Danish cohort [10]. Information on the modifying role
of age at onset in outcome has been inconsistent, but
our findings with higher mortality rates in the elderly
may be explained by increased occurrence of comor-
bidities and the reduced life expectancy in this age
group. Finally, our SMR was calculated from 1-year mor-
tality rates, which would expectedly be higher than e.g.
long-term mortality rates.
Although the lowered mortality rates within the more
recent years, in theory, could be explained by lead time
bias (meaning that an earlier diagnosis of e.g. mild or
early limited cutaneous SSc falsely appears to prolong
survival), several things suggest otherwise. First, the
mean age and comorbidity burden increased throughout
the years in our cohort. Secondly, the main causes of death
did not seem to change over the study period (although we
admittedly had low power to detect smaller differences).
One possibility underlying the increased survival could be
related to more aggressive management of e.g. hyperten-
sion and other comorbidities, possibly consistent with our
observations of more treated patients in the later study
Fig. 4 Temporal trends in sex-stratified mortality rates between 1995 and 2015. 1-year mortality rates for men and women
Table 4 Primary causes of death from 1995 to 2015
A00-B99 Certain infectious and parasitic diseases 5%
A31 Sepsis, other 4%
C00-D48 Neoplasms 15%
C34 Malignant neoplasm of bronchus and lung 4%
I00-I99 Diseases of the circulatory system 19%
I60-I69 Cerebrovascular diseases 3%
I20-I25 Ischaemic heart diseases 4%
I50 Heart failure 4%
J00-J99 Diseases of the respiratory system 24%
J96 Respiratory failure, not elsewhere classified 13%
J09-J18 Influenza and pneumonia 7%
K00-K93 Diseases of the digestive system 3%
M00-M99 Diseases of the musculoskeletal system
and connective tissue
9%
M34 Systemic sclerosis 8%
R00-R99 Symptoms, signs and abnormal clinical
and laboratory findings, not elsewhere
classified
16%
Footnote: Registered primary causes of death among SSc patients dying at
any time during the observational period. Only groups ≥3% are specified (due
to Danish laws about identifiable data)
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period. Currently available treatments for SSc related
internal organ involvement e.g. sclerodermal renal
crisis, pulmonary hypertension, and more aggressive
strategies for interstitial lung disease have also been
hypothesized to have changed the pattern of causes of
mortality in SSc [31, 37, 38]. We did not observe such
pattern changes during our 20-year study period,
although we observed a lower proportion of deaths
directly attributable to SSc in the late vs. early period.
Whether this may be a true finding or changes in
registration practice, is, however, unknown. Notably,
our study period was limited to 1995–2015 and did
not include the calendar time before the introduction
of recent treatment approaches. Cardiopulmonary
manifestations are currently believed to be among the
leading causes of death in SSc [8, 39, 40], which is also
supported by our study data. Still, nearly half of all
deaths were due to other causes, including approxi-
mately one seventh of all deaths being primarily attrib-
uted to a cancer diagnosis, underlining the need for a
consistent focus on non-SSc comorbidity. The associ-
ation between SSc and cancer is well recognized and
an area warranting more research [41, 42].
Study strengths and weaknesses
In general, Denmark is well-suited for epidemiological
studies of rare diseases, as the population is stable and
homogeneous, and as the Danish registries, including the
hospitalization registries, are accurate and complete
[43, 44]. Considering the findings of the validation
process and the high positive predictive value (94%) of
the diagnosis in the DNPR, this report is submitted on
the assumption that the SSc diagnosis is valid and ac-
curate. However, the validation process was not based
on a completely random selection of patient files due
to the infeasibility of doing so (restrained by Danish
laws). The principle strength of this study is the unse-
lected nature of the population. A major limitation is
the lack of validation of causes of death which were based
on clinicians’ adjudication. Furthermore, as the specific
patient context was not available via the National Causes
of Death Registry, it was not possible to classify cause of
death and organ involvement as SSc or non-SSc related.
It would have further strengthened the study if it had
been possible to discriminate lcSSc from dcSSc, but this
was unfortunately not feasible due to the lack of detail
in the ICD10 diagnostic coding. Moreover, for patients
with prevalent SSc immigrating to Denmark, these could
be mis-classified as incident cases in our study. However,
the proportion of patients being immigrants was low
and not significantly different in early and later study
periods, reducing the likelihood that our period results
were influenced hereby.
Conclusion
The incidence rate of SSc was approximately 24 per million
inhabitants in Denmark, which is somewhat greater than
that reported in many prior studies. Further, the incidence
rates increased slightly from 1995 to 2015. Over the same
period, 1-year mortality rates declined. The main causes of
death did not seem to change over the study period al-
though the demographic characteristics of patients with
newly diagnosed SSc changed, i.e. patients were older and
had more comorbidity at time of diagnosis in the later vs.
earlier years. As a seventh of all patients died from cancer,
more attention may be warranted on this disease in SSc
patients. Further epidemiological studies of SSc based on
uniform classification criteria over time are warranted to
confirm our hypothesis-generating findings.
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